News

G-CSF Stem Cell Therapy Safely Raises Frataxin Levels in Pilot Trial

Repeat use of G-CSF stem cell therapy, an approved medicine, was safe in adults with Friedreich’s ataxia and associated with significant elevations in frataxin protein and disease-related biomarkers, a pilot study in the U.K. reported. Because interventions that increase frataxin and reverse the harmful effects of the protein’s deficiency are…

Disease Progression May Differ Even in Groups With Similar FA Severity

Disease progression can vary significantly among people with Friedreich’s ataxia (FA) — even when patients are grouped by disease severity — a multicenter natural history study reported. Further, changes in symptom worsening may be smaller in older patients with the inherited, progressive disease. These findings, and others from the…

Metabolic Markers May Help in FA Diagnosis, Therapeutic Development

Some molecules involved in metabolism — all daily operations run by cells — are found in different amounts in patients with Friedreich’s ataxia (FA) versus healthy individuals and may be used as both diagnostic biomarkers and therapeutic targets, a small study suggests. The study, “Metabolomics analysis reveals dysregulation…